Skip to main content
Media Relations
Investor Relations
Home
Products
Microtiter Plate Assays
penKid
bio-ADM
Lightning
Science
Research Settings: Critical Conditions
Biomarkers for Critical Conditions
penKid: kidney function biomarker
bio-ADM: endothelial function biomarker
Pathophysiology
Acute Kidney Injury
Sepsis
Collaboration
Service Measurements
Network
Clinical Evaluation
Biomarker Out-Licensing
Company
About us
Team
Careers
Open Positions
News
Events
Investor Relations
Media Relations
Newsletter
Contact us
Resource Center
Downloads
Scientific Publications
Webinars
Role of Proenkephalin in Assessing Recovery from AKI and AKI-D
The Implementation of a Novel Kidney Function Biomarker in Clinical Routine
Using Proenkephalin as a Novel Biomarker to Estimate GFR
Using bio-ADM and penKid for Optimization of AHF Management in Daily Clinical Practice
Point-of-care Diagnostics in the Emergency Department: Better Patient Management
Sepsis in the Emergency Department: Recognizing High-Risk Patients With the Biomarker Bioactive Adrenomedullin
Overcoming the Limitations of Acute Kidney Injury (AKI) Diagnostics in the Emergency Department: the Biomarker Proenkephalin for Early Recognition of AKI
Blog
Search
(current)
Order
Contact us
Newsletter
Reset
111 results:
111.
sphingotec and GeneNews Limited/Innovative Diagnostics Laboratory (IDL) Sign a Licensing and Cooperation Agreement for the U.S. Market
SphingoTec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and…
Search results 111 until 111 of 111
previous
3
4
5
6
7
8
9
10
11
12
